Jessica L Crisp

US Patent:

20210403907, Dec 30, 2021

Filed:

Sep 13, 2021

Appl. No.:

17/473209

Inventors:

- New York NY, US
Ian PEIKON - Bethpage NY, US
Zachary GILBERT - Brooklyn NY, US
Andrey PISAREV - Brooklyn NY, US
Adam FRAITES - Long Beach Twp. NJ, US
Jessica CRISP - Phoenix AZ, US

International Classification:

C12N 15/11

Abstract:

Disclosed herein, in certain embodiments, are recombinant Arc and endogenous Gag polypeptides, and methods of using recombinant Arc and endogenous Gag polypeptides.

US Patent:

20190169127, Jun 6, 2019

Filed:

Dec 5, 2018

Appl. No.:

16/211051

Inventors:

- San Diego CA, US
Cheng-Chi Irene WANG - San Diego CA, US
Jason OLEJNICZAK - San Diego CA, US
Jessica CRISP - San Diego CA, US
Richard TRUONG - San Diego CA, US

International Classification:

C07D 213/75
C07D 413/12
C07D 413/14
C07D 417/04
C07D 403/12
C07D 409/12
C07D 401/12
C07D 405/12
C07D 471/04
C07D 487/04
A61P 35/04

Abstract:

Provided herein are compounds, pharmaceutical compositions, and methods of treatment for various diseases, such as cancer. In one aspect, the method comprises the treatment of brain cancers or metastatic cancers that spread to the brain.

US Patent:

20150359902, Dec 17, 2015

Filed:

Jan 29, 2014

Appl. No.:

14/764132

Inventors:

- Oaklnad CA, US
Jessica Crisp - San Diego CA, US
Roger Y. Tsien - La Jolla CA, US

International Classification:

A61K 47/48
A61K 38/06
A61K 49/00

Abstract:

Disclosed herein, the invention pertains to methods and compositions that find use in treatment, diagnosis, prognosis and characterization of disease and disease samples based on the ability of a disease sample to cleave a MTS molecule of the present invention. The MTS molecules of the present invention have a formula as disclosed herein and wherein A is a peptide with a sequence comprising 5 to 9 consecutive acidic amino acids, wherein the amino acids are selected from: aspartates and glutamates; B is a peptide with a sequence comprising 5 to 20 consecutive basic amino acids; X and Y are linkers; P is a pre-targeting moiety; M is a macromolecular carrier, C is a detectable moiety; and T is a compound for delivery to a target, including for example a therapeutic compound.